[go: up one dir, main page]

WO2000076488A3 - Use of a ppar agonist for treating type 1 diabetes - Google Patents

Use of a ppar agonist for treating type 1 diabetes Download PDF

Info

Publication number
WO2000076488A3
WO2000076488A3 PCT/GB2000/002330 GB0002330W WO0076488A3 WO 2000076488 A3 WO2000076488 A3 WO 2000076488A3 GB 0002330 W GB0002330 W GB 0002330W WO 0076488 A3 WO0076488 A3 WO 0076488A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
thiazolidine
dione
benzyl
ppar agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/002330
Other languages
French (fr)
Other versions
WO2000076488A2 (en
Inventor
Ameet Nathwani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to AU55470/00A priority Critical patent/AU5547000A/en
Publication of WO2000076488A2 publication Critical patent/WO2000076488A2/en
Publication of WO2000076488A3 publication Critical patent/WO2000076488A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for delaying or preventing the onset of Type 1 diabetes in a human or non-human mammal, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a PPAR agonist, such as, (+)-5-``4-` (3,4-dihydro- 6-hydroxy- 2,5,7,8-tetramethyl- 2H-1-benzopyran- 2-yl)methoxy!phenyl!Menthyl!-2,4- thiazolidinedione (or troglitazone), 5-`4-` (1-methylcycloheyxlmethoxy! benzyl! thiazolidine-2, 4-dione (or ciglitazone), 5-`(2-benzyl- 2,3-dihydrobenzopyran)- 5-ylmethyl) thiazolidine-2,4-dione (or englitazone), and 5-`4-`2 -(5-ethylpyridin- 2-yl)ethoxy! benzyl! thiazolidine-2,4- dione, or pioglitazone, or a pharmaceutically acceptable derivative thereof, to the patient in need thereof.
PCT/GB2000/002330 1999-06-14 2000-06-14 Use of a ppar agonist for treating type 1 diabetes Ceased WO2000076488A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55470/00A AU5547000A (en) 1999-06-14 2000-06-14 Novel treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9913782.0 1999-06-14
GBGB9913782.0A GB9913782D0 (en) 1999-06-14 1999-06-14 Novel compounds

Publications (2)

Publication Number Publication Date
WO2000076488A2 WO2000076488A2 (en) 2000-12-21
WO2000076488A3 true WO2000076488A3 (en) 2001-05-10

Family

ID=10855294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002330 Ceased WO2000076488A2 (en) 1999-06-14 2000-06-14 Use of a ppar agonist for treating type 1 diabetes

Country Status (3)

Country Link
AU (1) AU5547000A (en)
GB (1) GB9913782D0 (en)
WO (1) WO2000076488A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0109107A (en) * 2000-03-09 2002-12-03 Aventis Pharma Gmbh Therapeutic uses of ppar mediators
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
HK1220611A1 (en) 2013-03-15 2017-05-12 Bausch Health Ireland Limited Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN113388007A (en) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 Ultra-pure agonists of guanylate cyclase C, methods of making and using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228A1 (en) * 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
WO1997031907A1 (en) * 1996-02-28 1997-09-04 Glaxo Group Limited Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
WO1997043283A1 (en) * 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh New process for preparing troglitazone
WO1997045141A1 (en) * 1996-05-31 1997-12-04 Sankyo Company, Limited Remedy for autoimmune diseases
WO2000062766A2 (en) * 1999-04-15 2000-10-26 Smithkline Beecham Plc Uses of ppar-gamma agonists in neutrophil-induced diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228A1 (en) * 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
WO1997031907A1 (en) * 1996-02-28 1997-09-04 Glaxo Group Limited Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
WO1997043283A1 (en) * 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh New process for preparing troglitazone
WO1997045141A1 (en) * 1996-05-31 1997-12-04 Sankyo Company, Limited Remedy for autoimmune diseases
EP0953355A1 (en) * 1996-05-31 1999-11-03 Sankyo Company, Limited Remedy for autoimmune diseases
WO2000062766A2 (en) * 1999-04-15 2000-10-26 Smithkline Beecham Plc Uses of ppar-gamma agonists in neutrophil-induced diseases

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"THE MERCK MANUAL", 1999, MERCK RESEARCH LABORATORIES, XP002157021 *
BEALES P E ET AL: "Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.", EUROPEAN JOURNAL OF PHARMACOLOGY, (1998 SEP 18) 357 (2-3) 221-5., XP000978448 *
FUJIWARA, T. ET AL: "Suppressive effect of troglitazone on development of type 1 diabetes induced by multiple low-dose streptozotocin injection in mice.", DIABETOLOGIA, (1997) VOL. 40, NO. SUPPL. 1, PP. A311. MEETING INFO.: 16TH INTERNATIONAL DIABETES FEDERATION CONGRESS HELSINKI, FINLAND JULY 20-25, 1997, XP000978468 *
FUKUDA M. ET AL: "CS - 045, a new oral antidiabetic agent, prevents the development of cyclophosphamide-induced diabetes in NOD mice.", JOURNAL OF THE JAPAN DIABETES SOCIETY, (1994) 37/2 (127-130)., XP000978444 *
FUKUDA, MASAHIRO ET AL: "Antioxidants can prevent the development of type I diabetes in NOD mice", INT. CONGR. SER. (1995), 1100(DIABETES 1994), 1083-6, XP000978441 *
LESLIE R.D.G. ET AL: "The role of insulin resistance in the natural history of Type 1 diabetes.", DIABETIC MEDICINE, (1997) 14/4 (327-331)., XP000978464 *
OGAWA J ET AL: "Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice.", LIFE SCIENCES, (1999) 65 (12) 1287-96., XP000978446 *
SMISMANS, ANNICK ET AL: "Damaged rat beta cells discharge glutamate decarboxylase in the extracellular medium.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996) VOL. 228, NO. 2, PP. 293-297., XP000971968 *
TAKAMURA T ET AL: "Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes.", DIABETES RESEARCH AND CLINICAL PRACTICE, (1999 MAY) 44 (2) 107-14., XP000978465 *
TOMINAGA M ET AL: "Thiazolidinediones ( AD - 4833 and CS - 045 ) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.", ENDOCRINE JOURNAL, (1993 JUN) 40 (3) 343-9., XP000978449 *
TOMINAGA, MAKOTO (1) ET AL: "Effect of thiazolidinediones on insulin resistance of non- insulin -dependent and insulin -dependent diabetes mellitus model rats.", YAMAGATA MEDICAL JOURNAL, (1997) VOL. 15, NO. 1, PP. 35-43., XP000978587 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368562B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7378518B2 (en) 2003-03-07 2008-05-27 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368563B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

Also Published As

Publication number Publication date
WO2000076488A2 (en) 2000-12-21
GB9913782D0 (en) 1999-08-11
AU5547000A (en) 2001-01-02

Similar Documents

Publication Publication Date Title
WO2000076488A3 (en) Use of a ppar agonist for treating type 1 diabetes
CO5300392A1 (en) NEW COMPOSITION AND USE
CO4940420A1 (en) NEW METHOD OF TREATMENT
HK1053788A1 (en) Uses of ppar-gamma agonists in neutrophil-induced diseases
WO1997012580A3 (en) Novel composition containing an acid-labile benzimidazole and process for its preparation
BRPI0011674B8 (en) (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole crystal, pharmaceutical composition, and use of said crystal
NZ501260A (en) Treatment of diabetes with thiazolidinedione and metformin
WO2008130395A3 (en) Desferrithiocin analogue actinide decorporation agents
CO4940489A1 (en) NEW METHOD OF TREATMENT CINEMA ASSOCIATED WITH THE SAME IN MAMMALS
CA2297115A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
ZA984084B (en) Use of thiazolidinedione derivatives in the treatment of polycistic ovary syndrome gestational diabetes and disease states at risk for progressing to noninsulindependent diabetes mellitus
AU2000258410A1 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
AP1600A (en) Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
NZ522730A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
AP1814A (en) Tartrate salts of thiazolidinedione derivative.
WO2002036124A3 (en) Treatment and method using loratadine and montelukast
MX9805512A (en) Treatment and prevention of cardiac insulin resistance associated conditions.
HUP9902845A2 (en) Novel treatment of leptine resistance
US20040192737A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
PE20000881A1 (en) USE OF THIAZOLIDINDIONA AS A CARDIOPROTECTOR
YU14603A (en) Tartrate salt of thiazolidinedione derivative
US20020082284A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP